Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06814587 · ClinicalTrials.gov registry record

Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy

A clinical trial of Coronary Artery Disease and Coronary Artery Bypass Graft (CABG), sponsored by University of Texas Southwestern Medical Center.

Recruiting
Registry status
15
Enrollment target
1
Study location

NCT06814587 is a study of Coronary Artery Disease and Coronary Artery Bypass Graft (CABG) that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 15 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06814587, a study of Coronary Artery Disease and Coronary Artery Bypass Graft (CABG), is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.

RECRUITING
Registry status
15 participants
Enrollment target
1
Study location

Study Summary

This prospective, non-blinded, single-center, translational research study aims to validate a multimodal advanced imaging exam for cardiac viability. The protocol utilizes three distinct imaging modalities: Single Photon Emission Computed Tomography Myocardial Perfusion Imaging (SPECT MPI), 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), and Hyperpolarized Carbon-13 (HP-13C) Pyruvate Magnetic Resonance Imaging (MRI). Under this protocol, the SPECT MPI and FDG-PET exams will be used in combination to comprehensively assess myocardial viability. Concurrently, the HP-13C Pyruvate MRI will be utilized to provide additional insights into myocardial metabolism. The study will evaluate healthy volunteers to establish baseline parameters and patients with ischemic cardiomyopathy (ICM) before and after surgical revascularization.

Conditions Studied

Coronary Artery Disease Coronary Artery Bypass Graft (CABG)

Interventions

  • DIAGNOSTIC_TEST Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI)
  • DIAGNOSTIC_TEST [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
  • DIAGNOSTIC_TEST SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)

Study Locations (1)

Texas

  • University of Texas Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2024-07-01
Est. Completion 2026-06-30

Sponsor

University of Texas Southwestern Medical Center

837 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06814587

The ClinicalTrials.gov registry entry for NCT06814587 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (99% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 3 interventions - of which Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI) is the first listed.

NCT06814587 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06814587 about?

NCT06814587 is a clinical study titled "Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy". This prospective, non-blinded, single-center, translational research study aims to validate a multimodal advanced imaging exam for cardiac viability. The protocol utilizes three distinct imaging modalities: Single Photon Emission Computed Tomography Myocardial Perfusion Imaging (SPECT MPI), 18F-fluo...

What is the current status of trial NCT06814587?

This trial is currently recruiting. The enrollment target is 15 participants. The study started on 2024-07-01. Estimated completion is 2026-06-30.

What conditions does trial NCT06814587 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Coronary Artery Bypass Graft (CABG).

What interventions are being tested in trial NCT06814587?

The interventions under investigation include: Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI) (DIAGNOSTIC_TEST), [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) (DIAGNOSTIC_TEST), SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging) (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06814587?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06814587 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Coronary Artery Disease

All registered trials for this condition

Coronary Artery Bypass Graft (CABG)

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.